
Nadolol Quality Solutions Category: Cardiovascular





USP can support your development and manufacturing activities on Nadolol-based medicines with these existing and upcoming standards.

Official and Proposed Documentary Standards

MONOGRAPH 1

NADOLOL NEW Official as of 01-Dec-2023	
USP Nadolol RS	<u>USP-1449700</u>
USP Nadolol Related Compound A RS	<u>USP-1449711</u>
USP Nadolol Related Compound B RS	<u>USP-1449722</u>
USP Nadolol Related Compound C RS	<u>USP-1449733</u>
USP Nadolol Related Compound F RS	<u>USP-1449766</u>
USP Nadolol Related Compound G RS	<u>USP-1449777</u>

MONOGRAPH 2

NADOLOL TABLETS Official as of 31-Dec-2012	
USP Nadolol RS	<u>USP-1449700</u>

MONOGRAPH 3

NADOLOL AND BENDROFLUMETHIAZIDE TABLETS Official as of 01-May-2021	
USP Nadolol RS	<u>USP-1449700</u>
USP Bendroflumethiazide RS	<u>USP-1049000</u>
USP 2,4-Disulfamyl-5-Trifluoromethylaniline RS	<u>USP-1223005</u>

Disclaimer: USP Quality Solution Sheets are provided as a convenience and for informational purposes only. Labmix24 makes reasonable efforts to provide correct information but assumes no liability for the completeness, timeliness or accuracy of the information contained in each QSS. It is the responsibility of the user to verify the information. The US Pharmacopeia remains the official source of this information.



www.labmix24.com